Tailoring antiplatelet therapy based on pharmacogenomics: How well do the data fit?

JAMA

Volumn 302, Issue 8, 2009, Pages 896-897

  Bhatt, Deepak L ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; CYTOCHROME P450 2C19; PRASUGREL; TICAGRELOR; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; DRUG DERIVATIVE; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

ACUTE CORONARY SYNDROME; ARTERY DISEASE; DRUG EFFICACY; EDITORIAL; GENE DOSAGE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENOMICS; PRIORITY JOURNAL; SECONDARY PREVENTION; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE; THROMBOCYTE AGGREGATION; TREATMENT RESPONSE; CORONARY ARTERY DISEASE; DRUG EFFECT; GENETICS; NOTE; PHARMACOGENETICS;

ARYL HYDROCARBON HYDROXYLASES; CORONARY ARTERY DISEASE; HUMANS; PHARMACOGENETICS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 69249219295     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.1249     Document Type: Editorial

References (20)

1. MeadowsTA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res. 2007;100(9):1261-1275. (Pubitemid 46742917)
2. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038): 1329-1339.
3. Helton TJ, Bavry AA, Kumbhani DJ, Duggal S, Roukoz H, Bhatt DL. Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials. Am J Cardiovasc Drugs. 2007;7(4):289-297. (Pubitemid 47295838)
4. Connolly SJ, Pogue J, Hart RG, et al; ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360(20): 2066-2078.
5. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. JAmColl Cardiol. 2005;45(2):246-251. (Pubitemid 40094733)
6. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109(25):3171-3175.
7. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol. 2005;46(9): 1705-1709.
8. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354-362.
9. Simon T, Verstuyft C, Mary-Krause M, et al; French Registry of Acute STElevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events.NEngl J Med. 2009;360(4):363-375.
10. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J. 2009;30(8):916-922.
11. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373(9660):309-317.
12. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008;51(20):1925-1934. (Pubitemid 351636443)
13. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849-858.
14. Bhatt DL, Fox KA, Hacke W, et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-1717.
15. Bhatt DL. What makes platelets angry: diabetes, fibrinogen, obesity, and impaired response to antiplatelet therapy? J Am Coll Cardiol. 2008;52(13):1060-1061.
16. Giusti B, Gori AM, Marcucci R, et al. Relation of cytochrome P450 2C19 loss-of- function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol. 2009;103(6):806-811.
17. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009;119(19):2553-2560.
18. Pena A, Collet JP, Hulot JS, et al. Canweoverride clopidogrel resistance? Circulation. 2009;119(21):2854-2857.
19. Bhatt DL. Intensifying platelet inhibition-navigating between Scylla and Charybdis. N Engl J Med. 2007;357(20):2078-2081.
20. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008;358(10):999-1008. (Pubitemid 351347099)